What is the recommended anticoagulant and antiplatelet protocol for a patient undergoing lower‑limb angioplasty?

Anticoagulant and Antiplatelet Protocol for Lower Limb Angioplasty

After lower limb angioplasty, the combination of low-dose rivaroxaban (2.5 mg twice daily) plus low-dose aspirin (81 mg daily) is recommended to reduce both major adverse cardiovascular events (MACE) and major adverse limb events (MALE). 1

Periprocedural Anticoagulation

During the angioplasty procedure itself, intraprocedural anticoagulation is required:

• Unfractionated heparin (UFH): Administer 60 IU/kg IV bolus, with target activated clotting time (ACT) of 250-350 seconds without glycoprotein IIb/IIIa inhibitors 1
• Alternative options: Low molecular weight heparin (enoxaparin 0.75 mg/kg IV bolus if >12 hours since last subcutaneous dose) or bivalirudin (0.75 mg/kg bolus followed by 1.75 mg/kg/h infusion) 1
• Discontinue anticoagulation after the procedure unless specific thrombotic complications occur 1

Post-Procedural Antiplatelet/Antithrombotic Therapy

First-Line Recommendation (Class I)

Low-dose rivaroxaban 2.5 mg twice daily PLUS aspirin 81 mg daily is the strongest evidence-based regimen post-revascularization 1. This combination:

• Reduces MACE (myocardial infarction, stroke, cardiovascular death) 1
• Reduces MALE (acute limb ischemia, major amputation, urgent revascularization) 1
• Represents the most recent guideline update (2024) with Class I recommendation 1

Alternative Regimen (Class IIa)

Dual antiplatelet therapy (DAPT) with clopidogrel 75 mg daily PLUS aspirin 81 mg daily is reasonable for at least 1-6 months after endovascular revascularization 1. This regimen:

• Should be considered when rivaroxaban is contraindicated or not available 1
• Duration of 1-6 months is supported, though optimal duration remains somewhat variable in practice 1, 2
• After the initial 1-6 month period, transition to single antiplatelet therapy 1

Single Antiplatelet Therapy

If dual therapy or rivaroxaban combination is not feasible:

• Clopidogrel 75 mg daily alone is recommended as it may be preferred over aspirin for symptomatic PAD 1
• Aspirin 75-325 mg daily alone is an acceptable alternative 1

Special Considerations

Patients Requiring Full-Intensity Anticoagulation

For patients with another indication for anticoagulation (e.g., atrial fibrillation, mechanical heart valve) who are not at high bleeding risk:

• Add single antiplatelet therapy (aspirin 81 mg daily) to the therapeutic anticoagulation 1
• Avoid triple therapy (dual antiplatelet plus anticoagulation) due to excessive bleeding risk 1

Surgical Revascularization with Prosthetic Graft

After surgical bypass with prosthetic graft material:

• DAPT with clopidogrel plus aspirin may be reasonable for at least 1 month (Class IIb) 1
• For autologous vein grafts, vitamin K antagonists have been considered historically, though newer evidence supports antiplatelet-based regimens 3

What NOT to Do

Full-intensity oral anticoagulation alone (warfarin or therapeutic-dose DOACs) should NOT be used in PAD patients without another indication, as it does not reduce MACE or MALE and increases bleeding risk 1

Key Pitfalls to Avoid

• Do not use therapeutic-dose anticoagulation post-procedure unless there is a separate indication (atrial fibrillation, venous thromboembolism) 1
• Avoid switching between anticoagulants during the periprocedural period (e.g., UFH to LMWH), as this increases complications 1
• The rivaroxaban dose is specifically 2.5 mg twice daily (not the standard 20 mg dose used for atrial fibrillation)—this low-dose regimen is critical 1
• Monitor for bleeding risk as the rivaroxaban-aspirin combination does increase major bleeding compared to aspirin alone, though the cardiovascular and limb benefits outweigh this risk in most patients 1

Duration of Therapy

• Long-term therapy is recommended for patients with symptomatic PAD after revascularization 1
• The rivaroxaban-aspirin combination or DAPT should continue beyond the immediate post-procedural period for ongoing cardiovascular and limb protection 1
• After 1-6 months of DAPT (if used instead of rivaroxaban-aspirin), transition to single antiplatelet therapy for long-term management 1